



Ranjit Shahani,  
Vice Chairman and Managing Director,  
Novartis India Limited  
Sandoz House, Shivsagar Estate  
Dr. Annie Besant Road, Worli,  
Mumbai 400 018

Sent via email: ranjit.shahani@novartis.com

8 May, 2013

Dear Sir,

**Sub: Appointment of the broker for the proposed sale of equity shares of Novartis India Limited ("Company") by its promoter, Novartis AG ("Seller")**


---

Reference is made to our letter dated 27 March, 2013, in which we informed you that, subject to the receipt of relevant regulatory approvals, as may be applicable, and appropriate market conditions, we, the Seller, intend to reduce our shareholding in the Company, in accordance with and pursuant to Clause 40A of the Listing Agreement, by way of sale of equity shares through stock exchange mechanism in order to enable the Company to comply with the minimum public shareholding threshold prescribed under the SCRR, within the time period prescribed thereunder.


We hereby inform you, that Novartis AG has appointed Citigroup Capital Markets India Private Limited as the sole broker for the proposed sale of equity shares.

Yours Sincerely,

On behalf of the Seller



Jean-Baptiste Emery  
Authorized Signatory



Martin Morawietz  
Authorized Signatory